Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced plans to advance its investigational anti-interleukin-15 monoclonal antibody, TEV-'408, into a Phase 2b study in vitiligo, expected to begin in the fourth quarter of 2026.

The decision follows results from an ongoing Phase 1b open-label study in adults with active or stable non-segmental vitiligo. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area.

At week 24, nearly 75% of evaluable patients reported improvement in facial vitiligo, with half reporting "much" or "very much" improved. Additionally, 42% achieved F-VASI50 and 21% achieved F-VASI75. For total body vitiligo, 55% of patients reported improvement, while 7% achieved T-VASI50.

TEV-'408 was reported to be well-tolerated with no safety signals observed to date. The antibody is designed for quarterly subcutaneous dosing, administered every 12 weeks.

"TEV-'408 exemplifies the type of innovative, Teva-discovered program we are prioritizing as we continue to advance and strengthen our immunology pipeline," said Richard Francis, President and Chief Executive Officer of Teva.

Vitiligo is a chronic autoimmune disease that causes loss of skin pigmentation. The information above is based on a press release issued by Teva.